Display options
Cite
Rubattu S, Gallo G. The Natriuretic Peptides for Hypertension Treatment. High Blood Press Cardiovasc Prev. 2021;doi: 10.1007/s40292-021-00483-5.
Rubattu, S., & Gallo, G. (2021). The Natriuretic Peptides for Hypertension Treatment. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, . https://doi.org/10.1007/s40292-021-00483-5
Rubattu, Speranza, and Gallo, Giovanna. "The Natriuretic Peptides for Hypertension Treatment." High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension vol. (2021). doi: https://doi.org/10.1007/s40292-021-00483-5
Rubattu S, Gallo G. The Natriuretic Peptides for Hypertension Treatment. High Blood Press Cardiovasc Prev. 2021 Nov 02; doi: 10.1007/s40292-021-00483-5. Epub 2021 Nov 02. PMID: 34727352.
Copy Download .nbib Format: NLM
Share it on

High Blood Press Cardiovasc Prev. 2021 Nov 02; doi: 10.1007/s40292-021-00483-5. Epub 2021 Nov 02.

The Natriuretic Peptides for Hypertension Treatment.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

Speranza Rubattu, Giovanna Gallo

Affiliations

  1. Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. [email protected].
  2. IRCCS Neuromed, Pozzilli, Isernia, Italy. [email protected].
  3. Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.

PMID: 34727352 DOI: 10.1007/s40292-021-00483-5

Abstract

Hypertension is a common pathological condition predisposing to a higher occurrence of cardiovascular diseases and events. Unfortunately, treatment of hypertension is still suboptimal worldwide. More efforts are needed to implement the availability of anti-hypertensive drugs. The family of natriuretic peptides, including atrial and brain natriuretic peptides (ANP and BNP), play a key role on blood pressure regulation through the natriuretic, diuretic and vasorelaxant effects. A large number of experimental and human studies, ranging from pathophysiological to genetic investigations, supported ANP as the most relevant component of the family able to modulate blood pressure and to contribute to hypertension development. On this background, it is expected that ANP-based therapeutic approaches may give a significant contribution to the development of efficacious therapies against hypertension. Since native ANP cannot be administered due to its short half-life, several approaches were attempted over the years to overcome the difficulties inherent to the ANP instability. These approaches included ANP recombinant and fusion peptides, gene therapy, inhibition of ANP degradation by neprilysin inhibition, and designer peptides. The most relevant achievements in the field are discussed in this article. Based on the available evidence, therapies targeting ANP represent efficacious and clinically applicable anti-hypertensive agents.

© 2021. Italian Society of Hypertension.

Keywords: ANP; ARNi; Hypertension; MANP; NEP inhibitor; Natriuretic peptides

References

  1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. - PubMed
  2. Ives CW, Oparil S. What is the first choice for blood pressure treatment? Lancet. 2019 Nov 16;394(10211):1782–4. - PubMed
  3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group 2018. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. - PubMed
  4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 (S0140-6736(21)01330-1). - PubMed
  5. Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324(12):1190–200. - PubMed
  6. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94. - PubMed
  7. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230(4727):767–70. - PubMed
  8. Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698–717. - PubMed
  9. Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015;21(9):1048–53. - PubMed
  10. Volpe M, Rubattu S. Novel insights into the mechanisms regulating pro-atrial natriuretic peptide cleavage in the heart and blood pressure regulation: proprotein convertase subtilisin/kexin 6 is the corin activating enzyme. Circ Res. 2016;118(2):196–8. - PubMed
  11. Meyer M, Richter R, Forssmann WG. Urodilatin, a natriuretic peptide with clinical implications. Eur J Med Res. 1998;3(1–2):103–10. - PubMed
  12. Skelton WP 4th, Pi GE, Vesely DL. Four cardiac hormones cause death of human cancer cells but not of healthy cells. Anticancer Res. 2011;31(2):395–402. - PubMed
  13. Pandey KN. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function. Physiol Genom. 2018;50(11):913–28. - PubMed
  14. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008;101(3A):3–8. - PubMed
  15. Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18–25. - PubMed
  16. Moyes AJ, Hobbs AJ. C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci. 2019;20(9):2281. - PubMed
  17. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992;267(20):13928–32. - PubMed
  18. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999;56(2):502–8. - PubMed
  19. de Bold AJ, Bruneau BG, Kuroskide Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31(1):7–18. - PubMed
  20. Rubattu S, Stanzione R, Cotugno M, Bianchi F, Marchitti S, Forte M. Epigenetic control of natriuretic peptides: implications for health and disease. Cell Mol Life Sci. 2020;77(24):5121–30. - PubMed
  21. Rubattu S, Calvieri C, Pagliaro B, Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013;31(6):1061–72. - PubMed
  22. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77. - PubMed
  23. Špiranec Spes K, Chen W, Krebes L, Völker K, Abeßer M, Eder Negrin P, Cellini A, Nickel A, Nikolaev VO, Hofmann F, Schuh K, Schweda F, Kuhn M. Heart-microcirculation connection: effects of ANP (atrial natriuretic peptide) on pericytes participate in the acute and chronic regulation of arterial blood pressure. Hypertension. 2020;76(5):1637–48. - PubMed
  24. Forte M, Madonna M, Schiavon S, Valenti V, Versaci F, Zoccai GB, Frati G, Sciarretta S. Cardiovascular pleiotropic effects of natriuretic peptides. Int J Mol Sci. 2019;20(16):3874. - PubMed
  25. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81. - PubMed
  26. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7. - PubMed
  27. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378(6552):65–8. - PubMed
  28. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97(8):4239–44. - PubMed
  29. Fujii T, Hirota K, Yasoda A, Takizawa A, Morozumi N, Nakamura R, Yotsumoto T, Kondo E, Yamashita Y, Sakane Y, Kanai Y, Ueda Y, Yamauchi I, Yamanaka S, Nakao K, Kuwahara K, Jindo T, Furuya M, Mashimo T, Inagaki N, Serikawa T, Nakao K. Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death. PLoS ONE. 2018;13(3):e0194812. - PubMed
  30. Rubattu S, Evangelista A, Barbato D, Barba G, Stanzione R, Iacone R, Volpe M, Strazzullo P. Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J Hum Hypertens. 2007;21(10):822–4. - PubMed
  31. Cannone V, Cabassi A, Volpi R, Burnett JC Jr. Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease. Int J Mol Sci. 2019;20(13):3265. - PubMed
  32. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35(7):419–25. - PubMed
  33. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60(16):1558–65. - PubMed
  34. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006;48(3):499–505. - PubMed
  35. Chen C, Zhao Z, Xu J, Cao X, Guo S, Li J, Wang H, Hou S. Prokaryotic expression, purification and identification of recombinant human atrial natriuretic peptide. Sheng Wu Gong Cheng Xue Bao. 2016;32(9):1273–85. - PubMed
  36. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995;26(6 Pt 1):847–53. - PubMed
  37. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999;33(1 Pt 2):219–24. - PubMed
  38. Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, Marian AJ, Entman ML, Oka K, Chan L, O’Malley BW. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci USA. 2005;102(39):13789–94. - PubMed
  39. da Silva GJJ, Altara R, Booz GW, Cataliotti A. Atrial natriuretic peptide31–67: a novel therapeutic factor for cardiovascular diseases. Front Physiol. 2021;12:691407. - PubMed
  40. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994 Sep;90(3):1129–40. - PubMed
  41. Kangawa K, Tawaragi Y, Oikawa S, Mizuno A, Sakuragawa Y, Nakazato H, Fukuda A, Minamino N, Matsuo H. Identification of rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature. 1984;312(5990):152–5. - PubMed
  42. Nishi K, Sato Y, Miyamoto T, Toma M, Taniguchi R, Fukuhara R, Saijo S, Fujiwara H, Takatsu Y. Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure. J Cardiol. 2012;59(3):366–73. - PubMed
  43. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T; ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159(6):949–955.e1. - PubMed
  44. Hattori H, Minami Y, Mizuno M, Yumino D, Hoshi H, Arashi H, Nuki T, Sashida Y, Higashitani M, Serizawa N, Yamada N, Yamaguchi J, Mori F, Shiga T, Hagiwara N. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels. 2013;28(3):345–51. - PubMed
  45. Mitrovic V, Forssmann WG, Schnitker J, Felix SB. Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2018 Dec;5(6):1023–34. - PubMed
  46. Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36(12):715–23. - PubMed
  47. Meems LMG, Burnett JC Jr. Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci. 2016;1(7):557–67. - PubMed
  48. McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14(1):62–9. - PubMed
  49. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010;56(6):1152–9. - PubMed
  50. Chen H, Wan SH, Iyer SR, Cannone V, Sangaralinghham J, Nuetel J, Burnett JC Jr. A first in human study of MANP: a novel atrial natriuretic peptide analogue in human hypertension. Hypertension 2021 (in press). - PubMed
  51. Chen BY, Chen JK, Zhu MZ, Zhang DL, Sun JS, Pei JM, Feng HS, Zhu XX, Jin J, Yu J. AC-NP: a novel chimeric peptide with natriuretic and vasorelaxing actions. PLoS ONE. 2011;6(5):e20477. - PubMed
  52. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52(1):60–8. - PubMed
  53. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17(1):S37-43. - PubMed
  54. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607–13. - PubMed
  55. Kentsch M, Otter W, Drummer C, Nötges A, Gerzer R, Müller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51(3–4):269–72. - PubMed
  56. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–11. - PubMed
  57. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66. - PubMed
  58. Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, Pal P, Yang F, Hirschhorn E, Prescott MF, Hinder M, Langenickel TH. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69(1):32–41. - PubMed
  59. Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC Jr, Iyer S, Januzzi JL Jr. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73(11):1273–84. - PubMed
  60. Nougué H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, Launay JM, Cohen-Solal A, Vodovar N, Logeart D. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598–605. - PubMed
  61. Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13):2824. - PubMed
  62. Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, Sarzani R. Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287–97. - PubMed
  63. Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7:3487–96. - PubMed
  64. Rubattu S, Cotugno M, Forte M, Stanzione R, Bianchi F, Madonna M, Marchitti S, Volpe M. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. J Hypertens. 2018;36(9):1902–14. - PubMed
  65. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens. 2008;26(2):322–33. - PubMed
  66. Volpe M, Gallo G. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike? Eur Heart J. 2021;42(36):3753–5. - PubMed
  67. Volpe M, Tocci G, Battistoni A, Rubattu S. Angiotensin II receptor blocker neprilysin inhibitor (ARNI): new avenues in cardiovascular therapy. High Blood Press Cardiovasc Prev. 2015;22(3):241–6. - PubMed
  68. Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens. 2002;20(4):707–14. - PubMed
  69. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension. 2011;57(4):755–63. - PubMed
  70. Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004;43(4):489–94. - PubMed

Publication Types